Andrew M. Rogers

7.9k total citations · 1 hit paper
21 papers, 4.7k citations indexed

About

Andrew M. Rogers is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Andrew M. Rogers has authored 21 papers receiving a total of 4.7k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 10 papers in Pulmonary and Respiratory Medicine and 9 papers in Oncology. Recurrent topics in Andrew M. Rogers's work include Lung Cancer Treatments and Mutations (10 papers), Cancer Genomics and Diagnostics (4 papers) and Colorectal Cancer Treatments and Studies (3 papers). Andrew M. Rogers is often cited by papers focused on Lung Cancer Treatments and Mutations (10 papers), Cancer Genomics and Diagnostics (4 papers) and Colorectal Cancer Treatments and Studies (3 papers). Andrew M. Rogers collaborates with scholars based in United States, United Kingdom and Japan. Andrew M. Rogers's co-authors include Pasi A. Jänne, Jeffrey A. Engelman, James G. Christensen, Bruce E. Johnson, Neal I. Lindeman, Kreshnik Zejnullahu, Charles Lee, Xiao‐Jun Zhao, Youngchul Song and Tetsuya Mitsudomi and has published in prestigious journals such as Science, The Journal of Experimental Medicine and Journal of Clinical Oncology.

In The Last Decade

Andrew M. Rogers

20 papers receiving 4.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

2007 3.6k citations Jeffrey A. Engelman, Kreshnik Zejnullahu et al. Science profile →

Peers

Countries citing papers authored by Andrew M. Rogers

Since Specialization

Citations

This map shows the geographic impact of Andrew M. Rogers's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew M. Rogers with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew M. Rogers more than expected).

Fields of papers citing papers by Andrew M. Rogers

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew M. Rogers. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew M. Rogers. The network helps show where Andrew M. Rogers may publish in the future.

Co-authorship network of co-authors of Andrew M. Rogers

This figure shows the co-authorship network connecting the top 25 collaborators of Andrew M. Rogers. A scholar is included among the top collaborators of Andrew M. Rogers based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrew M. Rogers. Andrew M. Rogers is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Mass Cytometry as a Tool for Investigating Senescence in Multiple Model Systems 2023 ·Cells ·Amina Abdul‐Aziz, (unknown), (unknown), Hsiaochi Chang, (unknown), (unknown), Andrew M. Rogers, John C. Byrd, Erin Hertlein, Gregory K. Behbehani	3
2	Hematopoietic Cell Transplantation and Adoptive Cell Therapy in Peripheral T Cell Lymphoma 2020 ·Current Hematologic Malignancy Reports ·Andrew M. Rogers, Jonathan E. Brammer	12
3	BTK inhibitors and anti-CD20 monoclonal antibodies for treatment-naïve elderly patients with CLL 2020 ·Therapeutic Advances in Hematology ·Andrew M. Rogers, Jennifer A. Woyach	10
4	miR-196b target screen reveals mechanisms maintaining leukemia stemness with therapeutic potential 2018 ·The Journal of Experimental Medicine ·Sara E. Meyer, David E. Muench, Andrew M. Rogers, (unknown), (unknown), Eric O’Brien, John P. Perentesis, John G. Doench, Ashish Lal, Patrick J. Morris, Craig J. Thomas, Judy Lieberman, Edwina McGlinn, Bruce J. Aronow, Nathan Salomonis, H. Leighton Grimes	20
5	Acquired Gitelman Syndrome Secondary to Bendamustine Use. 2018 ·PubMed ·Andrew M. Rogers, (unknown), (unknown), Jie Tang	2
6	Calcineurin Orchestrates Lateral Transfer of Aspergillus fumigatus during Macrophage Cell Death 2016 ·American Journal of Respiratory and Critical Care Medicine ·Anand Shah, Shichina Kannambath, Susanne Herbst, Andrew M. Rogers, Simona Soresi, M. Carby, Anna Reed, Serge Mostowy, Matthew C. Fisher, Sunil Shaunak, Darius Armstrong‐James	50
7	Longitudinal analysis of the humoral response to Kaposi's sarcoma-associated herpesvirus after primary infection in children 2016 ·Journal of Medical Virology ·(unknown), Veenu Minhas, (unknown), (unknown), Andrew M. Rogers, Chipepo Kankasa, John T. West, Charles Wood	13
8	S82 ‘The Kiss of death’ – Calcineurin inhibitors prevent actin-dependent lateral transfer of Aspergillus fumigatus in necroptotic human macrophages 2015 ·Thorax ·Anand Shah, Shichina Kannambath, Susanne Herbst, Andrew M. Rogers, M. Carby, Anna Reed, Serge Mostowy, Sunil Shaunak, (unknown)	0
9	Transformed cell-specific induction of apoptosis by porcine circovirus type 1 viral protein 3 2014 ·Journal of General Virology ·Kenneth P. Hough, Andrew M. Rogers, Matija Zelic, (unknown), Destin W. Heilman	8
10	c-Met, epidermal growth factor receptor, and insulin-like growth factor-1 receptor are important for growth in uveal melanoma and independently contribute to migration and metastatic potential 2012 ·Melanoma Research ·Xinqi Wu, Jun Zhou, Andrew M. Rogers, Pasi A. Jänne, Elisa Benedettini, Massimo Loda, F. Stephen Hodi	37
11	Multiple Mutations and Bypass Mechanisms Can Contribute to Development of Acquired Resistance to MET Inhibitors 2011 ·Cancer Research ·Jie Qi, Michele McTigue, Andrew M. Rogers, Eugene Lifshits, James G. Christensen, Pasi A. Jänne, Jeffrey A. Engelman	168
12	Abstract 4736: Amplification of ERK2 mediates resistance to the novel irreversible EGFR inhibitor WZ4002 2011 ·Cancer Research ·Dalia Ercan, Wenjun Zhou, Masahiko Yanagita, Marzia Capelletti, Andrew M. Rogers, Yun Xiao, Nathanael S. Gray, Pasi A. Jänne	1
13	Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor 2010 ·Oncogene ·Dalia Ercan, Kreshnik Zejnullahu, Kimio Yonesaka, Yun Xiao, Marzia Capelletti, Andrew M. Rogers, Eugene Lifshits, Alyssa Brown, Charles Lee, James G. Christensen, David J. Kwiatkowski, Jeffrey A. Engelman, Pasi A. Jänne	181
14	Autocrine Production of Amphiregulin Predicts Sensitivity to Both Gefitinib and Cetuximab in EGFR Wild-type Cancers 2008 ·Clinical Cancer Research ·Kimio Yonesaka, Kreshnik Zejnullahu, Neal I. Lindeman, (unknown), David M. Jackman, Feng Zhao, Andrew M. Rogers, Bruce E. Johnson, Pasi A. Jänne	96
15	Mutations in the LKB1 tumour suppressor are frequently detected in tumours from Caucasian but not Asian lung cancer patients 2008 ·British Journal of Cancer ·Jussi Koivunen, (unknown), J. Lee, Andrew M. Rogers, (unknown), Xiao‐Jun Zhao, Katsuhiko Naoki, Isamu Okamoto, Kazuhiko Nakagawa, B.Y. Yeap, Matthew Meyerson, Kwok‐Kin Wong, William G. Richards, David J. Sugarbaker, Bruce E. Johnson, Pasi A. Jänne	124
16	Non-invasive detection of EGFR T790M in gefitinib/erlotinib resistant NSCLC 2008 ·Journal of Clinical Oncology ·Yanan Kuang, Andrew M. Rogers, (unknown), Mike Makrigiorgos, (unknown), (unknown), R Distel, Pasi A. Jänne	1
17	Application Forum: A Cost-Effective High-Throughput MicroRNA Profiling Service Based on Array and Non-Enzymatic Labeling Technologies 2008 ·BioTechniques ·Andrew M. Rogers, (unknown), (unknown), (unknown), Graham Speight	1
18	Comparison of genotyping with direct sequencing as a method to detect EGFR mutations in NSCLC 2008 ·Journal of Clinical Oncology ·Alison J. Holmes, Victoria A. Joshi, Yanan Kuang, Andrew M. Rogers, Pasi A. Jänne	2
19	MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling breakdown → 2007 ·Science ·Jeffrey A. Engelman, Kreshnik Zejnullahu, Tetsuya Mitsudomi, Youngchul Song, Courtney Hyland, Joon Oh Park, Neal I. Lindeman, (unknown), Xiao‐Jun Zhao, James G. Christensen, Takayuki Kosaka, Alison J. Holmes, Andrew M. Rogers, Federico Cappuzzo, Tony Mok, Charles Lee, Bruce E. Johnson, Lewis C. Cantley, Pasi A. Jänne	3570
20	A Rapid and Sensitive Enzymatic Method for Epidermal Growth Factor Receptor Mutation Screening 2006 ·Clinical Cancer Research ·Pasi A. Jänne, Ana M. Borras, Yanan Kuang, Andrew M. Rogers, Victoria A. Joshi, (unknown), Neal I. Lindeman, Jeffrey C. Lee, Balázs Halmos, Elizabeth A. Maher, R Distel, Matthew Meyerson, Bruce E. Johnson	183

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact